NEW YORK – Eyenovia, Inc., a pharmaceutical company specializing in preparations, announced today a reverse stock split of its common shares in a strategic move to comply with Nasdaq's minimum bid ...

Rigorous testing has resulted in observations of the Optejet’s durable base unit performing over 30,000 sprays, and 98% of ...

(NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet topical ophthalmic medication dispensing platform, today ...

Equities researchers at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of Eyenovia in a note issued to investors on Thursday, February 6th. HC Wainwright analyst M.

H.C. Wainwright maintained a neutral stance on Eyenovia (NASDAQ:EYEN) shares, reiterating a price target of $2.00. The firm's analyst, Matthew Caufield, highlighted the U.S. Food and Drug ...

Eyenovia, Inc. announced a 1-for-80 reverse stock split of its outstanding common stock, which was approved by its Board of Directors and stockholders. The split will take effect on January 31 ...

Eyenovia, Inc. announced on January 15, 2025, that leading proxy advisory firms ISS and Glass Lewis have advised stockholders to vote in favor of a proposed reverse stock split at a ratio between ...

Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20thNEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ ...

Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same period in the prior year, the firm earned ($0.18) earnings per share.

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its ...